Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 46 of 184 for:    pertuzumab

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (ATTILA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03811418
Recruitment Status : Withdrawn (Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP was not feasible.)
First Posted : January 22, 2019
Last Update Posted : November 26, 2019
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019